Kepivance™ (palifermin) Company Profile

12:14 EDT 22nd March 2019 | BioPortfolio

Kepivance™ (palifermin) is indicated to decrease the incidence and duration of severe oral mucositis (mouth sores) in patients withhematologic (blood) cancers undergoing high-dose chemotherapy, with or without radiation, followed by bone marrow transplant. The safety and efficacy of Kepivance™ have not been established in patients with nonhematologic malignancies.

News Articles [0 Results]


Drugs and Medications [1 Associated Drugs and Medications listed on BioPortfolio]

Kepivance [swedish orphan biovitrum ab (publ)]

These highlights do not include all the information needed to use Kepivance safely and effectively. See full prescribing information for KEPIVANCE. KEPIVANCE (palifermin) for injection, for intravenou...

PubMed Articles [0 Results]


Clinical Trials [31 Associated Clinical Trials listed on BioPortfolio]

PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation

This is an open-label, single-arm, multicentre study conducted in Spain to estimate the effectiveness of palifermin administered at a dose of 60 mg/kg/day IV for 3 consecutive days before ...

Palifermin for the Reduction of Oral Mucositis in Single-Dose Evaluation (PROMISE)

To evaluate whether palifermin (rHuKGF) administered as a single dose is non-inferior to 3 consecutive doses of palifermin in reducing the incidence of severe oral mucositis (World Health ...

Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults

Palifermin is a modified version of a naturally occurring human growth factor that is currently approved by the FDA to treat blood cancers. The purpose of this study is to determine wheth...

Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support

Open label palifermin will be administered to subjects who are at a risk of developing mucositis after radiotherapy and chemotherapy followed by blood stem cell support. The amount of pali...

Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma

Primary: 1. To evaluate the preliminary efficacy of palifermin in reducing the incidence and severity of oral mucositis (OM) in patients with sarcoma receiving multicycle ...

Companies [1 Associated Companies listed on BioPortfolio]

Kepivance™ (palifermin)

Kepivance™ (palifermin) is indicated to decrease the incidence and duration of severe oral mucositis (mouth sores) in patients withhematologic (blood) cancers undergoing high-dose chemotherapy, with...

More Information about "Kepivance™ (palifermin)" on BioPortfolio

We have published hundreds of Kepivance™ (palifermin) news stories on BioPortfolio along with dozens of Kepivance™ (palifermin) Clinical Trials and PubMed Articles about Kepivance™ (palifermin) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Kepivance™ (palifermin) Companies in our database. You can also find out about relevant Kepivance™ (palifermin) Drugs and Medications on this site too.

Quick Search


Relevant Topics

Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...

Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...

Corporate Database Quicklinks

Searches Linking to this Company Record